Tommy Carls Joins Proprio As VP of Product Management & Marketing: Medical Technology & Spine Industry Leader

Tommy Carls has joined Proprio leadership’s team, formally transitioning Carls from his role as Clinical Advisor to Vice President of Product Management & Marketing. Prior to serving as an independent medical device consultant, Tommy Carls served as the Vice President of Research and Development at Medtronic Spine & Biologics for 16 years.

Tommy Carls’s background also includes Vice President of Marketing for the Thoracolumbar Systems group at Medtronic, and Director of Marketing for the Image Guided Spinal Surgery group.
“Tommy is a globally recognized expert and industry trailblazer – we’re honored to have him transition into an in-house role as our VP of Product Management & Marketing,” noted Gabriel Jones, CEO and co-founder of Proprio. “His background in medical technology and knowledge of the spine industry will be essential to Proprio’s ongoing growth and success.”
“Proprio is creating the new way of seeing in spinal deformity procedures through the incorporation of immersive and intelligent technologies within the operating room,” Tommy Carls emphasized. “The application of these technologies can help level the playing field for all spine surgeons while benefiting patient care and subsequent outcomes. I look forward to being a part of this revolutionary team, and to continuing to help bring this vision to life.”
About Tommy Carls: Tommy Carls received his Bachelor of Science in mechanical engineering from Tulane University and his MBA from the University of Memphis. He most recently served as the Vice President of Research and Development at Medtronic Spine & Biologics where he was responsible for all engineering activities for the $2.8 Billion medical technology group.
Tommy Carls was formerly an independent medical device consultant, and served on Proprio’s Clinical Advisory Board before joining Proprio full-time as their Vice President of Product Management & Marketing in January 2022. He holds more than 80 patents, has led global teams of more than 150 engineers, and is held in high regard by the top clinical and industry leaders in the global spine market.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”